Literature DB >> 9535861

Enzymes catalyzing ubiquitination and proteolytic processing of the p105 precursor of nuclear factor kappaB1.

O Coux1, A L Goldberg.   

Abstract

Nuclear factor kappaB1 (NF-kappaB) is a heterodimeric complex that regulates transcription of many genes involved in immune and inflammatory responses. Its 50-kDa subunit (p50) is generated by the ubiquitin-proteasome pathway from a 105-kDa precursor (p105). We have reconstituted this proteolytic process in HeLa cell extracts and purified the responsible enzymes. Ubiquitination of p105 requires E1, and either of two types of E2s, E2-25K (for which p105 is the first proven substrate) or a member of the UBCH5 (UBC4) family. It also requires a new E3 of 50 kDa, which we call E3kappaB. This set of enzymes differs from the E2s and E3 reported by others to catalyze p105 ubiquitination in reticulocytes. The ubiquitinating enzymes purified here, together with 26S proteasomes, allowed formation of p50. Thus, the 26S proteasome provides all the proteolytic activities necessary for p105 processing. Interestingly, in the reconstituted system, as observed in cells, the C-terminally truncated form of p105, p97, was processed into p50 more efficiently than normal p105, even when both species were ubiquitinated to a similar extent. Therefore, some additional mechanism involving the C-terminal region of p105 influences the proteolytic processing of the ubiquitinated precursor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535861     DOI: 10.1074/jbc.273.15.8820

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase.

Authors:  A Orian; H Gonen; B Bercovich; I Fajerman; E Eytan; A Israël; F Mercurio; K Iwai; A L Schwartz; A Ciechanover
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

Review 2.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

3.  Reversal of established autoimmune diabetes by restoration of endogenous beta cell function.

Authors:  S Ryu; S Kodama; K Ryu; D A Schoenfeld; D L Faustman
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

4.  Evidence for the direct involvement of {beta}TrCP in Gli3 protein processing.

Authors:  Baolin Wang; Yanyun Li
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

5.  Shared pathways of IkappaB kinase-induced SCF(betaTrCP)-mediated ubiquitination and degradation for the NF-kappaB precursor p105 and IkappaBalpha.

Authors:  V Heissmeyer; D Krappmann; E N Hatada; C Scheidereit
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

6.  Relationship between the proteasomal system and autophagy.

Authors:  Alain Lilienbaum
Journal:  Int J Biochem Mol Biol       Date:  2013-03-31

7.  Structural motifs involved in ubiquitin-mediated processing of the NF-kappaB precursor p105: roles of the glycine-rich region and a downstream ubiquitination domain.

Authors:  A Orian; A L Schwartz; A Israël; S Whiteside; C Kahana; A Ciechanover
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

8.  NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism.

Authors:  Zhenqiang Yao; Lianping Xing; Brendan F Boyce
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

9.  Destabilization of Rb by human papillomavirus E7 is cell cycle dependent: E2-25K is involved in the proteolysis.

Authors:  Kwang-Jin Oh; Anna Kalinina; Srilata Bagchi
Journal:  Virology       Date:  2009-11-10       Impact factor: 3.616

10.  The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase.

Authors:  Kwang-Jin Oh; Anna Kalinina; Jing Wang; Keiko Nakayama; Keiichi I Nakayama; Srilata Bagchi
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.